University of Minnesota
Timeliness and Equity as Overlooked Quality Domains: Racial/Ethnic Disparities in Timeliness of Adjuvant Chemotherapy Receipt for Stage III Colon Cancer
Abstract
dc:description.abstractConsensus and evidence-based guidelines or quality measures provide treatment recommendations to promote standardized, high-quality health care. This research focused on a specific guideline which recommends stage III colon cancer patients to receive adjuvant chemotherapy within 4 months of diagnosis. It was endorsed by the National Quality Forum (NQF) in 2007 and has yet to be investigated for two important yet understudied health care quality domains: timeliness and racial/ethnic equity of care. Data from the linked Surveillance and Epidemiology and End Results (SEER) cancer registry and Medicare claims were used to investigate the following topics: 1. disparities in guideline-concordant adjuvant chemotherapy receipt, distinguishing between omitted and delayed chemotherapy as forms of guideline discordance; 2. racial/ethnic disparities in timeliness of adjuvant chemotherapy receipt, while assessing wait time disparities before and after tumor resection; 3. the impact of the guideline in changing rates of timely adjuvant chemotherapy receipt and racial differences in trends over time. This research provides important new insights into racial/ethnic equity of cancer care for White, Black, Hispanic, and Asian/Pacific Islander patients, with a nuanced focus on timeliness and delay that is overlooked in the quality of care literature.
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Joseph, Jennifer
Subjects
dc:subject × 6Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Dc Identifier Citation
- Joseph, Jennifer. (2018). Timeliness and Equity as Overlooked Quality Domains: Racial/Ethnic Disparities in Timeliness of Adjuvant Chemotherapy Receipt for Stage III Colon Cancer. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/218707.